Please note that this page will continue to exist as an archive
for research articles posted before the new site launched.
This is an edited version of an article reviewed by Emilie Henderson, B.Sc., and published on News-Medical.Net Oct. 12, 2022
This is an edited version of an article reviewed Emilie Henderson, B.Sc., and published on News-Medical.Net Oct. 11, 2022
Two new discoveries led by Cedars-Sinai Cancer investigators help improve the understanding of what drives the development of ovarian cancer and why some women's tumors do not respond to therapy.
This is an edited version of an article written by Kristie L. Kahl and published in OncLive Sept. 9, 2022
This is an edited version of an article written by Hayley Virgil and published in OncLive Sept. 11, 2022
Rucaparib (Rubraca) maintenance therapy improved progression-free survival (PFS) vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study....
The goal of the ATHENA-MONO trial was for investigators to assess the PFS of rucaparib and placebo across subgroups of patients with newly diagnosed ovarian cancer, including surgical outcomes by surgeon’s assessment and by the response to first-line chemotherapy by radiographic scans....
This is an edited version of an article written by Kristi Rosa and published in OncLive Sept. 15, 2022
This is an edited version of an article written by Ryan Scott and published in OncLive Oct. 12, 2022
This is an edited version of an article written by Jason Ryan and published in OncLive Oct. 17, 2022
November 19, 2022
Four Seasons Hotel Boston
Speakers will include:
Ursula Matulonis, MD, Leslie Garrett, MD, Katharine Esselen, MD,
Sharon Bober, Ph.D and author Donna Wiegle will share her "Teal on Wheels" Adventure!
SIGN UP NOW TO RESERVE YOUR SPOTS!
This is a FREE event for ovarian cancer patients, their caregivers, support community and those in the medical field working in gynecologic oncology.
Continental breakfast starts at 8am. Speaker presentations will run from 8:30 to 12:30 with breaks and the opportunity to visit our sponsors display tables.
A delicious plated lunch will be served from 12:30 to 2pm
Valet parking is available at the hotel at no cost with thanks to our sponsors support!
Ovations for the Cure
Saturday, September 10, 2022
11am to 2pm
We are so happy to share that after a 2 year wait, we will once again be offering our Cruise for a Cause luncheon cruise aboard the beautiful Spirit of Boston.
Relax and enjoy a wonderful buffet lunch on the Spirit of Boston. Then have a blast on the dance floor or venture outside to the outdoor deck space and enjoy the games scattered around the boat! There is no better way to see the beautiful Boston City Skyline than from the Harbor – all while supporting a good cause!
We have some amazing raffles, 50/50 chances and auctions going on as well!
Your ticket to this event will help support our Patient Service Programs which offer much needed support and services to women while they are undergoing treatment for ovarian cancer.
GET YOUR TICKETS EARLY - YOU DON'T WANT TO MISS THE FUN!
This is an edited version of an article by Kyle Doherty appearing in OncLive, July 2, 2022.
Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options. However, a new option for these patients whose disease harbors a high level of folate receptor α (FRα) may be emerging as the first-in-class antibody-drug conjugate mirvetuximab soravtansine displayed promising antitumor activity, according to results from the phase 3 SORAYA trial (NCT04296890) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. ...
“The results from SORAYA position were mirvetuximab soravtansine to become a practice-changing therapy for patients with platinum-resistant ovarian cancer [that is] high-grade serous and FRα positive, in a place in treatment where patients have very few options,” said Ursula A. Matulonis, MD, in an interview with OncologyLive.Mirvetuximab soravtansine is a well-tolerated drug for patients who have responses, and those responses are durable. They are deep responses, where we saw complete responses, which is really an unheard-of phenomenon in the treatment of platinum-resistant ovarian cancer.” ...
Based on the data from SORAYA, the FDA accepted and granted priority review to the biologic license application for mirvetuximab soravtansine and is expected to decide by November 28, 2022. To validate the findings, investigators have initiated the randomized phase 3 randomized MIRASOL trial (NCT04209855) vs investigator’s choice chemotherapy. ...
The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer, according to data from the dose-expansion portion of the phase 1 Study 101 trial (NCT03386942) presented during the 2022 ASCO Annual Meeting.
Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.
Rucaparib (Rubraca) elicited a significant improvement in progression-free survival (PFS) outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups in both the primary and exploratory analyses of the ATHENA-MONO trial (NCT03522246). Specifically, the PARP inhibitor demonstrated improvements in both homologous recombination deficient (HRD)-positive and HRD-negative populations, findings from which were presented at the 2022 ASCO Annual Meeting....
“Patients with measurable disease at baseline have further tumor reduction with rucaparib. [Additionally], rucaparib safety profile is consistent with prior studies,” Bradley J. Monk, MD, FACS, FACOG, professor in the Division of Gynecologic Oncology at the University of Arizona College of Medicine, medical director of the Gynecologic Program at US Oncology Research Network, and lead investigator of this study, said during the presentation.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a sensor that can be trained to sniff for cancer, with the help of artificial intelligence.
Although the training doesn’t work the same way one trains a police dog to sniff for explosives or drugs, the sensor has some similarity to how the nose works. The nose can detect more than a trillion different scents, even though it has just a few hundred types of olfactory receptors. The pattern of which odor molecules bind to which receptors creates a kind of molecular signature that the brain uses to recognize a scent.
Like the nose, the cancer detection technology uses an array of multiple sensors to detect a molecular signature of the disease. Instead of the signals going to the brain, they are interpreted by machine learning — a type of computer artificial intelligence.
MSK researchers led by Kravis WiSE Postdoctoral Fellow Mijin Kim and biomedical engineer Daniel Heller, head of the Cancer Nanomedicine Laboratory at MSK, built the technology using an array of sensors composed of carbon nanotubes. Carbon nanotubes are tiny tubes, nearly 100,000 times smaller than the width of a human hair. They are fluorescent, and the light they give off is very sensitive to minute interactions with molecules in their environment.Each nanotube sensor can detect many different molecules in a blood sample. By combining the many responses of the sensors, the technology creates a unique fluorescent pattern. The pattern can then be recognized by a machine-learning algorithm that has been trained to identify the difference between a cancer fingerprint and a normal one.
Need for Better Cancer Screening Tests
Tests that detect early-stage cancers using blood markers hold great promise for improving outcomes for people with cancer — especially those types, like ovarian cancer, that have few early signs or symptoms.Several serum biomarker tests for ovarian cancer are already in use. Unfortunately, these standalone biomarker measurements have proven to be ineffective at early detection. Currently, no screening strategy can identify ovarian cancer at an early enough stage to reduce mortality.
The links are available at the bottom of the screen for you to download the application instructions, the application itself, the health history form and the consent form. You can print it out and send it back to me via email or mail. If you have trouble opening the link or you are without the ability to print, please contact me at firstname.lastname@example.org so that I can send you a hard copy.
The acceptance process is not first-come, first-serve. Please make sure that if you are mailing the hard copy of your forms, it must be received by Tuesday, May 24th so that we can contact you by Friday, May 27th by email or 'phone to confirm your spot. We will have a wait list available.
Do not send any payment at this time - please wait until your spot has been confirmed.
· Again, only after you have been notified of your spot, please send your check for $250 (or any amount – we want all women to attend regardless of ability to pay) payable to: Turning the Tide Ovarian Cancer Retreats Inc.
NOTE: If you need to request a scholarship (assistance for payment) please check the box on the application form.
We so look forward to your application!
Here are the links to each document:
This is an edited version of an article published on ScienceDaily February 8, 2022.
An online symptom management tool that harnesses the problem-solving benefits of expressive writing could help women with ovarian cancer better manage complex symptoms, according to a new study led by a University of Pittsburgh and UPMC nurse-scientist.
This is a shortened version of an article written by Kyle Doherty and published in OncLive March 19, 2022